Health
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease The safety and tolerability profile of AUVELITY in agitation associated with dementia due to Alzheimer’s disease has been established across short-term and long-term trials AUVELITY was developed with FDA Breakthrough Therapy designation and evaluated by the FDA under Priority Review Company to host webcast Friday, May 1, at 8:00 AM East
About this update from Axsome Therapeutics, Inc.
[{"type":"image","alt":"Axsome Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Axsome Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":198,"url":"https://media.zenfs.com/en/globenewswire.com/f877923e5fbf4e5fb0d5937a043d2467"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vRTxlCkoAGJ1bw.3TR0iDw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI3Nw--/https://media.zenfs.com/en/globenewswire.com/f877923e5fbf4e5fb0d5937a043d2467","width":300,"height":198}},"lazy":false},{"type":"text","content":"AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease ","length":160,"tagName":"p"},{"type":"text","content":"The safety and tolerability profile of AUVELITY in agitation associated with dementia due to Alzheimer’s disease has been established across short-term and long-term trials ","length":172,"tagName":"p"},{"type":"text","content":"AUVELITY was developed with FDA Breakthrough Therapy designation and evaluated by the FDA under Priority Review","length":111,"tagName":"p"},{"type":"text","content":"Company to host webcast Friday, May 1, at 8:00 AM Eastern Time","length":62,"tagName":"p"},{"type":"text","content":"NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved AUVELITY® (dextromethorphan HBr and bupropion HCl) for the treatment of agitation associated with dementia due to Alzheimer’s disease.1 AUVELITY is a first-in-class treatment for Alzheimer’s disease agitation which targets the N-methyl D-aspartate (NMDA) and sigma-1 receptors.","length":548,"tagName":"p"},{"type":"text","content":"“The approval of our first-in-class medication for agitation associated with Alzheimer’s disease marks an important milestone for the millions of patients living with Alzheimer’s disease, their families, and their caregivers. We are very pleased to deliver to clinicians and patients a new, effective, FDA-approved treatment option, with a distinct mechanism of action, for this debilitating and critically underserved condition,” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Alz...